Naomi Aronson, PhD, is the Executive Director of Clinical Evaluation, Innovation, and Policy, Blue Cross & Blue Shield Association, and a member of the EXCITE International Advisory Council and the ISC.
Dr. Aronson leads BCBSA clinical effectiveness and policy engagement with government, regulatory agencies and policy consortia.Her areas of leadership include comparative effectiveness, patient centered research, safety surveillance, regulatory science and methodological standards.
Previously, Dr. Aronson led the development of the BCBSA Technology Evaluation Center (TEC), now the Center for Clinical Effectiveness (CCE), as a nationally recognized technology assessment program and an Evidence-based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ). She directed over 300 technology assessments and 20 evidence reports for AHRQ. Dr. Aronson is a member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI). She also serves on the PCORI Board of Governors Research Transformation Committee and the PCORI Rare Diseases Advisory Panel.
Dr. Aronson is a member of the Health Technology Assessment International Health Policy Forum, Institute of Medicine Genomics Roundtable, the National Business Group on Health Committee on Evidence-Based Benefit Design, the New Drug Development Paradigms (NEW DIGS) initiative of the MIT Center for Biomedical Innovation, Steering Committee of the Quality Assurance Pilot for Cancer CDx, and the Scientific Oversight Committee of the FDA Medical Device Epidemiology Network (MDEpiNet).
Executive Director, Clinical Evaluation, Innovation, and Policy, Blue Cross & Blue Shield Association